On August 10, 2023, Johnson & Johnson announced the FDA approval of TALVEYTM (talquetamab-tgvs)5,9,21, the world’s first bispecific antibody targeting GPRC5D/CD3, for the treatment of relapsed or refractory multiple myeloma in adult patients5. This evidence concerns the gene GPRC5D and AL amyloidosis.